Corvus Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.7092
- Today's High:
- $1.84
- Open Price:
- $1.83
- 52W Low:
- $0.607
- 52W High:
- $3.7
- Prev. Close:
- $1.86
- Volume:
- 216263
Company Statistics
- Market Cap.:
- $162.06 million
- Book Value:
- 1.049
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -24.48%
- Return on Equity TTM:
- -59%
Company Profile
Corvus Pharmaceuticals Inc had its IPO on 2016-03-23 under the ticker symbol CRVS.
The company operates in the Healthcare sector and Biotechnology industry. Corvus Pharmaceuticals Inc has a staff strength of 29 employees.
Stock update
Shares of Corvus Pharmaceuticals Inc opened at $1.83 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.71 - $1.84, and closed at $1.71.
This is a -8.06% slip from the previous day's closing price.
A total volume of 216,263 shares were traded at the close of the day’s session.
In the last one week, shares of Corvus Pharmaceuticals Inc have slipped by -19.72%.
Corvus Pharmaceuticals Inc's Key Ratios
Corvus Pharmaceuticals Inc has a market cap of $162.06 million, indicating a price to book ratio of 0.576 and a price to sales ratio of 0.
In the last 12-months Corvus Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-30892000. The EBITDA ratio measures Corvus Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Corvus Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -24.48% with a return of equity of -59%.
In Q1, Corvus Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Corvus Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.91 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Corvus Pharmaceuticals Inc’s profitability.
Corvus Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.2654. Its price to sales ratio in the trailing 12-months stood at 0.
Corvus Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $58.20 million
- Total Liabilities
- $7.03 million
- Operating Cash Flow
- $4.60 million
- Capital Expenditure
- $34000
- Dividend Payout Ratio
- 0%
Corvus Pharmaceuticals Inc ended 2024 with $58.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $58.20 million while shareholder equity stood at $48.87 million.
Corvus Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $7.03 million in other current liabilities, 5000.00 in common stock, $-315561000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.65 million and cash and short-term investments were $34.47 million. The company’s total short-term debt was $1,263,000 while long-term debt stood at $0.
Corvus Pharmaceuticals Inc’s total current assets stands at $34.47 million while long-term investments were $20.23 million and short-term investments were $24.81 million. Its net receivables were $467000.00 compared to accounts payable of $7.03 million and inventory worth $0.
In 2024, Corvus Pharmaceuticals Inc's operating cash flow was $4.60 million while its capital expenditure stood at $34000.
Comparatively, Corvus Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.71
- 52-Week High
- $3.7
- 52-Week Low
- $0.607
- Analyst Target Price
- $3.83
Corvus Pharmaceuticals Inc stock is currently trading at $1.71 per share. It touched a 52-week high of $3.7 and a 52-week low of $3.7. Analysts tracking the stock have a 12-month average target price of $3.83.
Its 50-day moving average was $2.27 and 200-day moving average was $1.57 The short ratio stood at 0.49 indicating a short percent outstanding of 0%.
Around 397.8% of the company’s stock are held by insiders while 4590.7% are held by institutions.
Frequently Asked Questions About Corvus Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.